The Oncosearch | Oncotarget

Imipridones ONC201/ONC206 + RT/TMZ triple (IRT) therapy reduces intracranial tumor burden, prolongs survival in orthotopic IDH-WT GBM mouse model, and suppresses MGMT Research Paper

Lanlan Zhou, Leiqing Zhang, Jun Zhang, Laura Jinxuan Wu, Shengliang Zhang, Andrew George, Marina Hahn, Howard P. Safran, Clark C. Chen, Attila A. Seyhan, Eric T. Wong, Wafik S. El-Deiry

Published Mar 20, 2025 · Vol. 16, No. 1 · pp. 230-248

Keywords: glioblastoma multiforme, IDH, ONC201, ONC206, MGMT, temozolomide, radiotherapy

Integrated stress response (ISR) activation and apoptosis through HRI kinase by PG3 and other p53 pathway-restoring cancer therapeutics Research Paper

Xiaobing Tian, Wafik S. El-Deiry

Published Jul 26, 2024 · Vol. 15, No. 1 · pp. 614-633

Keywords: mutant p53, integrated stress response (ISR), ATF4, HRI, ClpP

A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs Research Paper

Kelsey E. Huntington, Anna Louie, Lanlan Zhou, Wafik S. El-Deiry

Published Sep 11, 2021 · Vol. 12, No. 20 · pp. 1980-1991

Keywords: cytokine profiling, inflammatory response, chemokine, growth factor, immune profiling

Correction: Discovery and clinical introduction of first-in-class imipridone ONC201 Correction

Joshua E. Allen, C. Leah B. Kline, Varun V. Prabhu, Jessica Wagner, Jo Ishizawa, Neel Madhukar, Avital Lev, Marie Baumeister, Lanlan Zhou, Amriti Lulla, Martin Stogniew, Lee Schalop, Cyril Benes, Howard L. Kaufman, Richard S. Pottorf, B. Rao Nallaganchu, Gary L. Olson, Fahd Al-Mulla, Madeleine Duvic, Gen Sheng Wu, David T. Dicker, Mala K. Talekar, Bora Lim, Olivier Elemento, Wolfgang Oster, Joseph Bertino, Keith Flaherty, Michael L. Wang, Gautam Borthakur, Michael Andreeff, Mark Stein, Wafik S. El-Deiry

Published Jun 22, 2021 · Vol. 12, No. 21 · pp. 2231-2231

TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic Priority Research Paper

Marie D. Ralff, Aakash Jhaveri, Jocelyn E. Ray, Lanlan Zhou, Avital Lev, Kerry S. Campbell, David T. Dicker, Eric A. Ross, Wafik S. El-Deiry

Published Oct 6, 2020 · Vol. 11, No. 42 · pp. 3753-3769

Keywords: ONC201, TRAIL, breast cancer, death receptors, apoptosis

ONC201 kills breast cancer cells in vitro by targeting mitochondria Research Paper

Yoshimi Endo Greer, Natalie Porat-Shliom, Kunio Nagashima, Christina Stuelten, Dan Crooks, Vishal N. Koparde, Samuel F. Gilbert, Celia Islam, Ashley Ubaldini, Yun Ji, Luca Gattinoni, Ferri Soheilian, Xiantao Wang, Markus Hafner, Jyoti Shetty, Bao Tran, Parthav Jailwala, Maggie Cam, Martin Lang, Donna Voeller, William C. Reinhold, Vinodh Rajapakse, Yves Pommier, Roberto Weigert, W. Marston Linehan, Stanley Lipkowitz

Published Apr 6, 2018 · Vol. 9, No. 26 · pp. 18454-18479

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP Priority Research Paper

Avital Lev, Amriti R. Lulla, Jessica Wagner, Marie D. Ralff, Joshua B. Kiehl, Yan Zhou, Cyril H. Benes, Varun V. Prabhu, Wolfgang Oster, Igor Astsaturov, David T. Dicker, Wafik S. El-Deiry

Published Sep 12, 2017 · Vol. 8, No. 47 · pp. 81776-81793

ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways Research Paper

Xiao Ni, Xiang Zhang, Cheng Hui Hu, Timothy Langridge, Rohinton s. Tarapore, Joshua E. Allen, Wolfgang Oster, Madeleine Duvic

Published Jun 27, 2017 · Vol. 8, No. 37 · pp. 61761-61776

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma Clinical Research Papers

Isabel Arrillaga-Romany, Andrew S. Chi, Joshua E. Allen, Wolfgang Oster, Patrick Y. Wen, Tracy T. Batchelor

Published May 12, 2017 · Vol. 8, No. 45 · pp. 79298-79304

ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells Research Paper

Xun Yuan, Dhonghyo Kho, Jing Xu, Ambikai Gajan, Kongming Wu, Gen Sheng Wu

Published Feb 17, 2017 · Vol. 8, No. 13 · pp. 21626-21638

Discovery and clinical introduction of first-in-class imipridone ONC201 Review

Joshua E. Allen, C. Leah B. Kline, Varun V. Prabhu, Jessica Wagner, Jo Ishizawa, Neel Madhukar, Avital Lev, Marie Baumeister, Lanlan Zhou, Amriti Lulla, Martin Stogniew, Lee Schalop, Cyril Benes, Howard L. Kaufman, Richard S. Pottorf, B. Rao Nallaganchu, Gary L. Olson, Fahd Al-Mulla, Madeleine Duvic, Gen Sheng Wu, David T. Dicker, Mala K. Talekar, Bora Lim, Olivier Elemento, Wolfgang Oster, Joseph Bertino, Keith Flaherty, Michael L. Wang, Gautam Borthakur, Michael Andreeff, Mark Stein, Wafik S. El-Deiry

Published Sep 1, 2016 · Vol. 7, No. 45 · pp. 74380-74392

TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo Research Paper

Georg Karpel-Massler, MaÃ¯mouna BÃ¢, Chang Shu, Marc-Eric Halatsch, M.-Andrew Westhoff, Jeffrey N. Bruce, Peter Canoll, Markus D. Siegelin

Published Oct 12, 2015 · Vol. 6, No. 34 · pp. 36456-36471

Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status Research Paper

Martin Michaelis, Florian Rothweiler, Nadine LÃ¶schmann, Mohsen Sharifi, Taravat Ghafourian, Jindrich Cinatl Jr.

Published Feb 13, 2015 · Vol. 6, No. 19 · pp. 17605-17620

The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity Research Paper

Jessica Wagner, Christina Leah Kline, Richard S. Pottorf, Bhaskara Rao Nallaganchu, Gary L. Olson, David T. Dicker, Joshua E. Allen, Wafik S. El-Deiry

Published Jan 5, 2015 · Vol. 5, No. 24 · pp. 12728-12737

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Imipridones ONC201/ONC206 + RT/TMZ triple (IRT) therapy reduces intracranial tumor burden, prolongs survival in orthotopic IDH-WT GBM mouse model, and suppresses MGMT Research Paper

Integrated stress response (ISR) activation and apoptosis through HRI kinase by PG3 and other p53 pathway-restoring cancer therapeutics Research Paper

A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs Research Paper

Correction: Discovery and clinical introduction of first-in-class imipridone ONC201 Correction

TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic Priority Research Paper

ONC201 kills breast cancer cells in vitro by targeting mitochondria Research Paper

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP Priority Research Paper

ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways Research Paper

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma Clinical Research Papers

ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells Research Paper

Discovery and clinical introduction of first-in-class imipridone ONC201 Review

TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo Research Paper

Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status Research Paper

The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Imipridones ONC201/ONC206 + RT/TMZ triple (IRT) therapy reduces intracranial tumor burden, prolongs survival in orthotopic IDH-WT GBM mouse model, and suppresses MGMT Research Paper

Integrated stress response (ISR) activation and apoptosis through HRI kinase by PG3 and other p53 pathway-restoring cancer therapeutics Research Paper

A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs Research Paper

Correction: Discovery and clinical introduction of first-in-class imipridone ONC201 Correction

TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic Priority Research Paper

ONC201 kills breast cancer cells in vitro by targeting mitochondria Research Paper

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP Priority Research Paper

ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways Research Paper

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma Clinical Research Papers

ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells Research Paper

Discovery and clinical introduction of first-in-class imipridone ONC201 Review

TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo Research Paper

Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status Research Paper

The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity Research Paper